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Neuronal DNA damage response-associated dysregulation of signalling pathways and cholesterol
metabolism at the earliest stages of Alzheimer-type pathology
Aims: Oxidative damage and an associated DNA damage
response (DDR) are evident in mild cognitive impairment
and early Alzheimer’s disease, suggesting that neuronal
dysfunction resulting from oxidative DNA damage may
account for some of the cognitive impairment not fully
explained by Alzheimer-type pathology.Methods: Frontal
cortex (Braak stage 0–II) was obtained from the Medical
Research Council’s Cognitive Function and Ageing Study
cohort. Neuroneswere isolated from eight cases (four high
and four low DDR) by laser capture microdissection and
changes in the transcriptome identified by microarray
analysis. Results: Two thousand three hundred seventy-
eight genes were significantly differentially expressed
(1690 up-regulated, 688 down-regulated, P < 0.001) in
cases with a high neuronal DDR. Functional grouping
identified dysregulation of cholesterol biosynthesis,
insulin andWnt signalling, and up-regulation of glycogen
synthase kinase 3β. Candidate genes were validated by
quantitative real-time polymerase chain reaction. Cer-
ebrospinal fluid levels of 24(S)-hydroxycholesterol associ-
ated with neuronal DDR across all Braak stages (rs = 0.30,
P = 0.03). Conclusions: A persistent neuronal DDR may
result in increased cholesterol biosynthesis, impaired
insulin andWnt signalling, and increased GSK3β, thereby
contributing to neuronal dysfunction independent of
Alzheimer-type pathology in the ageing brain.
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Introduction
Population-based studies have shown that age-associated
cognitive decline often occurs in individuals with low
levels of either classical Alzheimer-type neuropathology
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or other neurodegenerative pathologies [1]. Oxidative
damage to nucleic acids is evident in mild cognitive
impairment (MCI) and early Alzheimer’s disease (AD)
[2–4], suggesting that oxidative stress is an early contribu-
tor to neuronal dysfunction, which either independently
of, or interacting with, early Alzheimer-type pathology
results in cognitive impairment. Oxidative DNA damage
induces a DNA damage response (DDR), which is charac-
terized by the activation of DNA–protein kinase catalytic
subunit (DNA–PKcs) and the phosphorylation of the
histone H2AX (γH2AX) [5]. Previous investigation of the
Medical Research Council’s Cognitive Function and
Ageing Study (MRC CFAS) cohort has demonstrated high
levels of oxidative stress and an associated DDR occur at
the earliest stages of Alzheimer pathology [6], as defined
by low Braak and Braak neurofibrillary tangle stage [7],
and an increased neuronal DDR at these early pathologi-
cal stages is associated with cognitive impairment and
neuronal senescence [8].
Various candidate mechanisms may underlie neuronal
vulnerability and initiate adverse cellular processes
several years before eventual cognitive decline. Signalling
dysregulation has been implicated in the pathogenesis of
AD [9,10], and large-scale genome-wide association
study (GWAS) studies have identified potential novel
pathways [11]; however, the contribution of these cell
processes to cognitive impairment remains to be defined.
Population-based neuropathology studies allow unbiased
assessment of the relationship of cellular and molecular
pathologies to dementia and enables early stages of clas-
sical pathologies to be investigated. By identifying novel
associations, these population-based approaches have
the potential to identify new biomarkers and therapeutic
strategies [12,13].
Having demonstrated the population variation in the
neuronal DDR in individuals with little or no Alzheimer-
type pathology and the association with cognitive impair-
ment [8], this study aimed to identify the gene expression
changes associated with the neuronal DDR, which may
contribute to neuronal dysfunction in the ageing brain.
Laser capture microdissection (LCM) of neurones from
human post-mortem material combined with microarray
technology enables the neuronal transcriptome of
samples to be simultaneously assessed, and changes in
gene expression identified. Although a number of studies
have reported microarray data in normal ageing and AD
[14–18], to date, no study has specifically characterized
the gene expression profile of neurones with high levels of
a DDR (DNA–PKcs and γH2AX) at low Braak and Braak
stages. Our findings identify a major transcriptional
response with potentially important implications for
neuronal dysfunction and cognitive decline independent
of classical Alzheimer-type pathology in the ageing brain.
Materials and methods
Human CNS tissue
CNS tissue was obtained from MRC CFAS, following
Research Ethics Committee approval (REC ref 12/EM/
0118). The structure of the CFAS neuropathology cohort
has been previously described and reviewed [10]. Brains
were dissected following a standard protocol [19] and
neuropathological lesions assessed as part of the core
CFAS neuropathology study using a modified protocol
from the Consortium to Establish a Registry of Alzhei-
mer’s Disease (CERAD) [20] (http://www.cfas.ac.uk).
Braak and Braak stage 0–II, frozen frontal cortex (FCx)
was available for 39 cases with an average age at death of
82 years (range 70–102 years), median post-mortem
delay of 17.5 h [interquartile range (IQR 10–24 h] and
tissue pH 6.6 (IQR pH 6.3–6.9). Individuals in the study
were regularly interviewed and underwent extensive cog-
nitive assessment [1,21]. Dementia status at death was
determined on the basis of all information available for
each participant [22]. Within this cohort, 14 participants
had dementia, 22 had no dementia and 3 participants had
an unknown dementia status at death due to the lack of
information in the years preceding death.
Cerebrospinal fluid (CSF)
CSF was collected post-mortem from one centre of the
CFAS cohort (98 cases), centrifuged at 2000 g for 10 min,
aliquoted and stored at −80°C until analysis. The cohort
comprised 30 cases Braak and Braak stages 0–II [mean
(standard deviation)], [80.5 (7.0)], 50 cases Braak and
Braak stages III–IV [88.6 (6.5)], and 18 cases Braak and
Braak stage V–VI [86.3 (6.1)]. The neuronal and astrocyte
DDR in these cases was previously assessed [6], and all
cases were previously screened for ApoE genotype [23].
Only one participant reported taking statins at their last
interview.
LCM of neurones
Gene expression analysis was performed on neurones iso-
lated from 10 cases (5 high neuronal DDR and 5 lowDDR)
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using laser capturemicroscopy (LCM) (Figure 1), based on
previous investigation of the neuronal DDR (DNA–PKcs
and γH2AX) in this cohort [8]. Details of cases used in the
microarray study are shown in Table 1. Validation experi-
ments were performed on LCM-isolated neurones from the
remaining 29 CFAS cases. Frozen sections (7 μm) were
fixed in ice cold acetone for 3 min and stained with
Toludine Blue for 1 min. Sections were dehydrated in a
graded series of ethanol (70, 95 and 100%), extensively
cleared in xylene and air dried for 1 h. Approximately,
1000 pyramidal neurones were isolated from each
case using a PixCell II LCM system (Life Technologies,
Paisley, UK). Total RNA was extracted using the PicoPure
RNA extraction kit according to the manufacturer’s
protocol (Life Technologies), with typical yields of 100 ng
of RNA. The quantity (NanoDrop 1000 spectropho-
tometer, Thermo Scientific, Wilmington, DE USA) and
quality (Agilent Bioanalyser 2100, RNA 6000 Pico
LabChip; Agilent, Palo Alto, CA, USA) of the starting
RNA were analysed. Sterile solutions made with
diethylpyrocarbonate (DEPC)-treated water and RNAse-
free conditions were used throughout this protocol.
RNA amplification and microarray hybridization
Total RNAwas annealed to an oligo-d(T) primer with aT7
polymerase binding site. After generation of double-
stranded cDNA, copy RNA (cRNA) was transcribed which
then formed the RNA template for a second round of
amplification. At the end of this round, after synthesis of
double-stranded cDNA, biotin-labelled cRNA was pre-
pared using the Affymetrix Gene Chip (Affymetrix, Santa
Clara, CA, USA) in vitro transcription labelling kit. Follow-
ing clean-up of the biotin-labelled cRNA the material was
assayed (Agilent Bioanalyser 2100) to ensure sufficient
RNA of appropriate quality had been prepared. Labelled
cRNA (12.5 μg) was fragmented and applied to HGU133
Plus 2.0 gene microarrays and hybridized over 16 h at
45°C in a rotating oven at 60 rpm. Post hybridization
washing and sample staining was carried out using the
Fluidics Station 400 and the Gene Chip Operating System.
Figure 1. Laser capture microdissection (LCM) of neurones. Toludine blue positive neurones were isolated (a) before and (b) after LCM, as
indicated by the arrows.
Table 1. MMSE score, gender, Aβ neuropathology, proportion of
neurones (%) with a DDR and RIN of cases used in the microarray
study
MMSE Sex
Diffuse
plaque
score
Neuritic
plaque
score γH2AX DNA–PKcs RIN
Low DDR
30 M 2 0 20 37 5.3
26 M 0 0 31 18 2.6
23 M 0 0 22 35 2.6
30 F 1 0 52 38 5.3
26 M 0 0 40 29 3.3
High DDR
6 F 2 0 44 100 2.3
20 M 0 0 75 91 5.3
0 F 1 0 73 88 4.3
21 M 1 0 74 72 4.3
20 F 0 0 72 80 2.5
Cases in bold were removed from the final analysis: low-DDR cases
sample outlier, high DDR case with Pick’s disease.
DDR, DNA damage response; DNA–PKcs, DNA–protein kinase cata-
lytic subunit; RIN, RNA integrity number.
Neuronal DNA damage response at earliest Alzheimer’s stages 3
© 2015 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Gene chips were scanned using the GC3000 7G scanner
and data processed for quality control using Expression
Console software (Affymetrix) and further analysis was
carried out using Qlucore Omics Explorer (Qlucore, Lund,
Sweden).
Microarray analysis
The Robust Multi-array Average (RMA) algorithm was
used for data normalization and univariate and principal
component analyses to determine intensity distribution
and eliminate sample outliers [24]. Significant differen-
tially expressed genes (P < 0.001) were analysed using
Qlucore Omics Explorer. The Database for Annotation
Visualisation and Integrated Discovery bioinformatics
programme (DAVID)was used to group genes according to
their function and to assign genes to specific functional
pathways [25].
Validation of microarray data: quantitative
real-time polymerase chain reaction (qPCR)
RNA was extracted from LCM-ed neurones in additional
frozen FCx cases, which had not been used for the
microarray studies. qPCR was performed using IDT
PrimeTime qPCR assays (Integrated DNA Technologies,
Glasgow, UK) containing 50 ng cDNA, 500 nM primers,
250 nM probe, and Brilliant qPCR mix (Agilent,
Stockport, UK) in a total volume of 10 μl, for more details
of primer sequences see Table 2. Following denaturation
at 95°C for 10 min the products were amplified (40 cycles
at 95°C for 30 s and 60°C for 60 s) using anMX3000P RT
PCR System (Stratagene, Paisley, UK). β-actin was ampli-
fied on each plate to normalize expression levels of target
genes between different samples using the ΔΔCt calcula-
tion (ABI) and to assess assay reproducibility.
Immunohistochemistry
To confirm neuronal expression of proteins encoded by
the candidate genes, immunostaining was performed
using a standard avidin biotinylated enzyme complex
(ABC) method, and the signal visualized with
diaminobenzidine (Vector Laboratories, Peterborough,
UK). A summary of the primary antibodies used is shown
in Table 3.
Table 2. Quantitative real-time polymerase chain reaction primer/probe sequence
Gene Sequence
DHCR24 Probe 5′-FAM-CATCTGGAAGCCATGCACGCTG-3′
Primer 1 5′-GTACAAGGAGCCATCAAACATC-3′
Primer 2 5′-AGGCAGCTGGAGAAGTTTG-3′
GSK3B Probe 5′-FAM-ACCACTCAAGAACTGTCAAGTAATCCACC-3′
Primer 1 5′-ACGGGACCCAAATGTCAAAC-3′
Primer 2 5′-GAGGAGGAATAAGGATGGTAGC-3′
HMGCR Probe 5′-FAM-ACCAACCTACTACCTCAGCAAGCCT-3′
Primer 1 5′-TCCTTGAACACCTAGCATCTG-3′
Primer 2 5′-CTGCACCATGCCATCTATAGAG-3′
IGFR1 Probe 5′-FAM-TGAGGCCTTCCTTCCTGGAGATCA-3′
Primer 1 5′-CTCCATCTCCTCTTTGATGCTG-3′
Primer 2 5′-CCAGACAACTGTCCTGACAT-3′
INSR Probe 5′-FAM-CTCCATCCATGACAAATTTCAACACCTGT-3′
Primer 1 5′-GTTGTCGGGTTGATCCAGAT-3′
Primer 2 5′-AAATCACCAGCTTGGCAGA-3′
NFL Probe 5′-FAM-AGGAAGAGGAGGCAGCTGAAGAGG-3′
Primer 1 5′-AGGAGGAGAAGGACAAGGA-3′
Primer 2 5′-TTGGTTTCCTCTCCTTCTTCAC-3′
WNT3 Probe 5′-FAM-TGGTGCCCTACTTGCAGGTGTG-3′
Primer 1 5′-CCAGGAGTGTATTCGCATCT-3′
Primer 2 5′-ATGAGACTTCGCTGAATCCG-3′
ACTB Probe 5′-FAM-CCATGTACGTTGCTATCCAGGCTGT-3′
Primer 1 5′-CCAGTGGTACGGCCAGA-3′
Primer 2 5′-GCGAGAAGATGACCCAGAT-3′
ACTB, actin, beta; DHCR24, 24-dehydrocholesterol reductase; GSK3B, glycogen synthase kinase 3β; HMGCR, HMG–CoA reductase; IGFR1,
insulin growth factor receptor 1; INSR, insulin receptor; NFL, neurofilament light.
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Western blotting
Frozen FCx from the array cases was homogenized in Tris
extraction buffer (10 mM Tris-HCl pH 7.4, 0.8M sodium
chloride, 1 mM ethylene glycol tetraacetic acid (EGTA),
10% sucrose, 0.1 mM phenylmethanesulphonyl fluoride
(PMSF), 2 μg/ml aprotonin, 10 μg/ml leupeptin, 5 μg/ml
pepstatin, 40 mM β-glycerophosphate, 50 mM sodium
fluoride, 200 μM sodium orthovanadate) and centrifuged
at 14 000 rpm for 30 min at 4°C. The protein content of
the supernatant was measured using the bicinchoninic
acid method and equal protein amounts (20 μg) analysed
by Western blot analysis. Proteins were separated by
sodiumdodecyl sulphate-polyacrylamide gel electrophore-
sis and transferred to nitrocellulose (BioRad Laboratory,
Hemel Hempstead, UK). Membranes were incubated over-
night with anti-neurofilament light (NFL; 1:2500; New
England Biolabs, Hitchin, UK) or anti-Wnt3 (1:500;
Abcam,Cambridge,UK) followedby the appropriate horse-
radish peroxidise-linked secondary antibody (1:1000) and
visualized by enhanced chemiluminescence detection.
To confirm equal protein loading, the membrane was
reprobed for β-actin (1:5000; Abcam). Protein expression
levelswere determined by densitometry of the appropriate,
subsaturated band using G:BOX Chemi (Syngene, Cam-
bridge, UK) and the results normalized to β-actin.
24(S)-hydroxycholesterol ELISA
Levels of 24(S)-OHC were quantitated by enzyme linked
immunosorbent assay (elisa) (Enzo Life Sciences UK Ltd,
Exeter, UK) in all available CSF from one centre of the
CFAS cohort (98 cases), according to the manufacturer’s
instructions.
Statistical analysis
Spearman’s correlation coefficient was calculated to test
associations between continuous variables. Analyses
were performed and graphs obtained using IBM® spss®
Statistics 21 (Armonk, NY, USA) and statistical package
stata, version 12 (College Station, TX, USA). To test the
possibility of 24(S)-OHC levels as a risk factor for demen-
tia, logistic regression was used, and to test if possession
of the ApoEε4 allele was a risk factor for decreased
24(S)-OHC, we used multiple linear regression analysis
with 24(S)-OHC as a dependent variable. All analyses
were adjusted by age at death and sex. All tests were
two-tailed, 95% confidence intervals (CI) were calculated
for the odds ratio (OR) and for the linear regression
coefficients (β).
Results
DDR-associated changes in the neuronal
transcriptome
The transcription profiles of laser-captured neurones from
high- and low-DDR cases were generated using Human
Genome U133 Plus 2.0 Arrays, which comprise 1.3 × 106
unique oligonucleotide sequences, including >47 000
transcripts and variants of 33 000 genes. Between 32%
and 45%of the probe set sequenceswere present across all
samples [mean (range)]: low neuronal DDR [36% (32–
45%)]; high neuronal DDR [40% (37–43%)].
Gene expression analyses are sensitive to the presence
of sample outliers, therefore rigorous quality control
procedures were used to ensure the highest possible level
of quality for both datasets. One low-DDR sample
outlier was identified by visual inspection after clustering
the samples using hierarchical clustering and one
high DDR case with Pick’s disease was excluded on
review of the neuropathology, both cases were removed
from subsequent analysis (Figure 2). The RMA was
re-analysed after these two cases were removed and
principal components analysis was performed on the
significant, differentially expressed genes (the expression
dataset is freely available at Gene Expression Omnibus,
accession number GSE66333). Transcript clusters
showed no association with age, gender, post-mortem
delay or pH.
Two thousand three hundred seventy-eight genes
(1690 up-regulated, 688 down-regulated) were
Table 3. Antibody source and specificity
Antibody Isotype Dilution (time, temp) Supplier
NFL Rabbit IgG 1:50 (60 min, RT) AbCam, UK
GSK3B Rabbit IgG 1:10 (60 min, RT) Sigma, UK
HMGCR Rabbit IgG 1:100 (60 min, RT) AbCam, UK
IRS1 Rabbit IgG 1:50 (60 min, RT) Santa Cruz, UK
SREBP2 Rabbit IgG 1:100 (60 min, RT) AbCam, UK
Wnt-3a Rabbit IgG 1:50 (60 min, RT) AbCam, UK
GSK3B, glycogen synthase kinase 3β; HMGCR, HMG–CoA reductase;
IgG, immunoglobulin G; IRS1, insulin receptor substrate 1; RT, room
temperature; SREBP, sterol regulatory element binding proteins.
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significantly differentially expressed (P < 0.001) in cases
with a high DDR (Supplementary Tables 1 and 2). Func-
tional grouping analysis identified the dysregulation of
genes associated with the cellular response to stress, the
synapse, signalling, ubiquitin-mediated proteolysis, trans-
port, the cytoskeleton and transcription. Pathway analysis
identified significant up-regulation of Wnt signalling
transcripts (P = 0.004) and down-regulation of insulin
signalling associated transcripts (P = 0.029) in cases with
a high neuronal DDR.
NFL transcripts had the greatest fold change (FC) (NFL
probe set 221805_at, FC = 36.03, P = 0.0002; probe set
221801_x_at, FC = 13.87, P = 0.0001; probe set
221916_at, FC = 5.89, P = 0.0001). Glycogen synthase
kinase 3β (GSK3B) transcripts were also significantly
up-regulated in caseswith a high neuronal DDR (probe set
226191_at, FC = 4.19, P = 0.00004).
DDR-associated dysregulation of insulin
signalling pathway transcripts
Further interrogation of the microarray dataset with
less stringent parameters (P < 0.05) confirmed the
neuronal DDR-associated dysregulation of insulin signal-
ling and identified insulin signalling-associated changes
in gene expression, including down-regulation of insulin
receptor (IR probe set 213792_at, FC = −1.05,
P = 0.049), insulin growth factor receptor 1 (IGFR1
probe set 203628_at, FC = −1.1, P = 0.013), insulin
growth factor 2 (IGF2 probe set 202410_at, FC = −1.1,
P = 0.022 and probe set 210881_at, FC = −1.1,
P = 0.007), insulin growth factor binding protein 5
(IGFBP5 probe set 203425_at, FC = −1.1, P = 0.0016),
phosphoinositide-3-kinase CD (PIK3CD probe set
211230_at, FC = −1.2, P = 0.031) and up-regulation of
insulin degrading enzyme (IDE probe set 203327,
FC = 1.1, P = 0.006).
DDR-associated activation of the cholesterol
biosynthesis pathway
Analysis of the transcription profiles of laser-captured
neurones from high neuronal DDR cases compared with
low neuronal DDR at the less stringent parameters
(P < 0.05) also identified activation of the cholesterol
synthesis pathway, namely significant overexpression of
six of the 10 genes encoding enzymes driving the
biosynthesis of cholesterol from acetyl CoA: acetoacetyl-
CoA transferase 1 (ACAT1 probe set 205412_at,
FC = 1.2, P = 0.004), HMG–CoA synthase (HMGCS1
probe set 221750_at, FC = 1.1, P = 0.008), HMG–CoA
reductase (HMGCR probe set 202539_s_at, FC = 4.5,
P = 0.0008 and probe set 202540_s_at, FC = 1.2,
P = 0.005), farnesyl diphosphate synthase (FDPS probe
set 201275_at, FC = 1.1, P = 0.002), squalene synthase
(FDFT1 probe set 210950_s_at, FC = 1.1, P = 0.012)
and 24-dehydrocholesterol reductase (DHCR24 probe set
200862_at, FC = 1.2, P = 0.005). In the brain, choles-
terol biosynthesis is regulated by sterol regulatory
element binding factors (SREBF), also known as sterol
regulatory element binding proteins (SREBP). A high
neuronal DDR was associated with the down-regulation
of SREBF1 (probe set 1558875_at, FC = −1.46,
P = 0.0004) and SREBF2 (probe set 201247_at,
FC = −1.1, P = 0.050; probe set 242748_at, FC = −1.1,
P = 0.001).
Figure 2. Gene expression analysis of cases with a high neuronal
DNA damage response (DDR). (a) Principal component analysis of
microarray data. One sample outlier in the low-DDR group
(indicated by the arrow) and one Pick’s disease case in the high
DDR group (indicated by the arrow head) were removed from
subsequent analysis. (b) Heat map depicting up-regulated (green)
and down-regulated (red) gene expression changes (P < 0.001). A
high neuronal DDR was associated with the up-regulation of 1690
genes and the down-regulation of 688 genes.
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Validation of microarray candidates
Candidate genes playing key roles in the pathways of
interest or which showed significant altered expression
were validated by qPCR on LCM-isolated neurones from all
additional cases from the CFAS Braak and Braak stage 0–II
cohort, which contained high-quality RNAas indicated by
the absence of excessive degradation of the ribosomal
RNA (19/29 additional cases). Decreasing expression of
IR (rs = −0.565, P = 0.028) and IGFR1 (rs = −0.704,
P = 0.004), and increasing expression of NFL (rs = 0.633,
P = 0.004), GSK3B (rs = 0.572, P = 0.011), wingless-type
MMTV integration site family, member 3a (WNT3A,
rs = 0.539, P = 0.017), HMGCR (rs = 0.450, P = 0.053)
andDHCR24 (rs = 0.458,P = 0.049)were associatedwith
an increasing neuronal DDR (proportion of γH2AX+ neu-
rones) (Table 4).
Neuronal expression of the protein encoded by selected
candidate genes, namely NFL (Figure 3a), insulin receptor
substrate1 (IRS1) (Figure 3b),GSK3β (Figure 3c),Wnt-3a
(Figure 3d), HMGCR (Figure 3e) and SREBP2 (Figure 3f)
was confirmed by immunohistochemistry. Furthermore,
significantly higher levels of NFL (P = 0.003) and signifi-
cantly lower levels of Wnt3a (P = 0.007) were associated
with ahighneuronal DDR, as detected byWestern blotting
of protein extracts from the array cases (Figure 4).
CSF levels of 24(S)-OHC associate with the
neuronal DDR and inversely associate with
Braak and Braak stage
As cholesterol plays a key role in synapse formation and
function [26], the study was extended to assess CSF levels
of 24(S)-OHC across all Braak and Braak stages in all
available CSF samples from one well-characterized centre
of the CFAS cohort [6]. Use of this larger cohort enabled
the association between cholesterol turnover and the
DDR, Braak and Braak stage, ApoEε4 genotype and cog-
nitive impairment to be investigated. CSF levels of 24(S)-
OHC negatively correlated with increasing Braak and
Braak stage (rs = −0.29, P = 0.040) (Figure 5a): Braak
stage 0–II (median 2.58 ng/ml; minimum–maximum:
0.16–9.28), Braak stage III–IV (1.90 ng/ml; 0.15–7.99)
and Braak stage V–VI (0.63 ng/ml; 0.02–4.35). Levels of
24(S)-OHC significantly correlated with both an astrocyte
DDR (rs = 0.43, P = 0.001) and a neuronal DDR
(rs = 0.30, P = 0.033) across all Braak and Braak stages
(Figure 5b,c).
Levels of 24(S)-OHCwere not a significant risk factor for
clinical dementia (OR = 1.12, 95% CI 0.82; 1.53,
P = 0.491). Possession of at least one ApoEε4 allele was
not significantly associated with increased levels of 24(S)-
OHC (β = 0.49, 95% CI −0.77; 1.75, P = 0.435). CSF
levels of 24(S)-OHC were weakly associated with brain pH
(rs = 0.14, P = 0.341) and post mortem delay (PMD)
(rs = −0.12, P = 0.402).
Discussion
Age-associated cognitive decline often occurs in individu-
als with low levels of conventional dementia-associated
pathologies (Aβ plaques, neurofibrillary tangles, vascular
lesions, synucleinopathy) [1,27]. Braak and Braak staging
describes an anatomical progression of neurofibrillary
tangles, in which tangles that are restricted to mesial tem-
poral lobe structures may precede clinico-pathological AD
by many years [7]. The current study investigated
prefrontal cortex as it is affected relatively late in the AD
process, thereby allowing us to identify potential gene
expression changes at early Braak and Braak stages before
the onset of classical AD-associated neuropathological
changes.We have previously demonstrated an association
between the neuronal DDR and cognitive impairment in
cases with little or no Alzheimer’s neuropathology, and
shown that high levels of a neuronal DDR correlate with
lower Mini Mental State Examination (MMSE) scores [8].
The present population-based study extends this previous
finding and demonstrates that the neuronal response to
DNA damage at the earliest stages of Alzheimer’s pathol-
ogy (Braak and Braak stage 0–II) is associated with
dysregulation of intracellular signalling pathways and
Table 4. Neuronal DNA damage response-associated gene changes
Gene
Microarray qPCR
FC P-value rs P-value
NFL 36.03 0.0002 0.633 0.004
GSK3B 4.19 0.00004 0.572 0.011
IR −1.05 0.049 −0.565 0.028
IGFR1 −1.1 0.013 −0.704 0.004
WNT3A 2.66 0.0009 0.539 0.017
HMGCR 4.5 0.0008 0.450 0.053
DHCR24 1.2 0.005 0.458 0.049
DHCR24, 24-dehydrocholesterol reductase; FC, fold change; GSK3B,
glycogen synthase kinase 3β;HMGCR, HMG–CoA reductase; IGFR1,
insulin growth factor receptor 1; IR, insulin receptor; qPCR, quanti-
tative real-time polymerase chain reaction; rs, Spearman’s rho corre-
lation coefficient.
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Figure 3. Immunohistochemical assessment of protein expression encoded by candidate genes. Neuronal expression of (a) neurofilament
light (NFL), (b) IRS1, (c) glycogen synthase kinase 3β (GSK3β), (d) Wnt-3a and (e) HMG–CoA reductase (HMGCR). (f) sterol regulatory
element binding proteins (SREBP)2 was associated with both neurones (arrow) and astrocytes (arrow head). Scale bar represents 50 μm.
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cholesterol biosynthesis, which may contribute to
neuronal dysfunction and cognitive impairment inde-
pendent of established Alzheimer pathology in the ageing
brain.
Insulin resistance has been linked to several
neurodegenerative diseases, including AD [9,28–32]. Low
concentrations of insulin, reduced receptor density and
dysregulation of insulin signalling have all been reported
in AD [33,34] and with increasing Braak and Braak stage
in the ageing brain [10,35]. Furthermore, administration
of insulin has been shown to improve memory in AD
patients [36] suggesting a potential therapeutic avenue for
dementia treatment. In the present transcriptomic study a
high neuronal DDRwas associated with the dysregulation
of insulin/IGF and Wnt signalling pathways. Defects in
both signalling pathways have been postulated to contrib-
ute to the pathogenesis of AD and dementia [9,37,38].
Although pathway analysis of the microarray data iden-
tified significant up-regulation of Wnt signalling associ-
ated transcripts in cases with a high neuronal DDR,
protein expression was significantly lower in these cases,
Figure 4. Protein expression encoded by candidate genes. Western
blot analysis of total protein extracts demonstrated significant
up-regulation of neurofilament light (NFL) (68 kDa) and
down-regulation of Wnt-3a (39 kDa) in cases with a high neuronal
DNA damage response (DDR). **P < 0.01. AU, arbitrary units.
Figure 5. Cholesterol turnover correlates with increased levels of both astrocyte and neuronal DNA damage response (DDR) and inversely
associates with Braak stage. Cerebrospinal fluid (CSF) levels of 24(S)-OHC (a) inversely associated with increasing Braak and Braak stage,
and positively associated with both (b) an astrocytic DDR (rs = 0.43, P = 0.001)and (c) a neuronal DDR (rs = 0.30, P = 0.033). Braak group
1 = Braak and Braak stage 0–II, Braak group 2 = Braak and Braak stage III–IV, Braak group 3 = Braak and Braak stage V–VI. AU = arbitrary
units.
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suggesting post-transcriptional regulation of Wnt expres-
sion. Both insulin/IGF and Wnt signalling negatively
regulate the activity of GSK3β [39], expression of which
was significantly up-regulated in cases with a high
neuronal DDR. The GSK3 hypothesis of AD proposes
that GSK3β over-activation plays a key role in the
hyperphosphorylation of tau, increased β-amyloid pro-
duction and neuronal dysfunction [40]. We propose that
increased levels of oxidative stress lead to a neuronal DDR,
which is associated with the down-regulation of insulin/
IGF and Wnt signalling, resulting in increased GSK3β
activity and ultimately leading to neuronal dysfunction
and cognitive impairment, independent of local
Alzheimer-type pathology in the ageing brain.
Increasing evidence suggests AD represents a metabolic
disease in which brain glucose utilization and energy
production are impaired [32–34,41]. Dysfunction of the
insulin/IGF signalling pathway impacts neuronal growth,
survival, differentiation, synapse formation, energy
metabolism, gene expression, protein synthesis and
cytoskeletal assembly [31]. Cytoskeletal disruption is a
prominent feature of neurodegenerative diseases, includ-
ing AD [42,43]. Expression of NFL was significantly
up-regulated in cases with a high neuronal DDR, both at
the gene (ranging from 5- to 36-fold increase) and protein
levels (fourfold increase), suggesting that abnormal accu-
mulation of this cytoskeletal protein may contribute to
neuronal dysfunction by impacting axonal transport.
Oxidative stress is one of the earliest events in AD, with
implications as an important mediator in the onset, pro-
gression and pathogenesis of the disease [2–4]. The pro-
posed sources of oxidative stress include abnormal
mitochondria, redox transition metals and oxysterols
[44,45]. In the brain, cholesterol is converted to the
oxysterol 24(S)-OHC, which is considered a marker of
cholesterol turnover [46,47], and which is elevated in the
CSF of patients with MCI [48–50]. In the current study,
CSF levels of 24(S)-OHCwere highest in cases with little or
no Alzheimer-type pathology, and correlated with the
neuronal DDR. We propose that high levels of the pro-
oxidant 24(S)-OHC are one potential source of oxidative
stress, which may contribute to an elevated neuronal
response to oxidative DNA damage, resulting in the acti-
vation of the neuronal cholesterol biosynthesis pathway
to maintain axons, dendrites and synapses at low Braak
and Braak stages [26,51]. However, while increased cho-
lesterol biosynthesis may preserve neuronal integrity at
low Braak stages, high levels of 24(S)-OHC may also
promote the progression of tau pathology [52] and
increase Aβ neurotoxicity [45] in the ageing brain. We
also demonstrate a significant reduction in 24(S)-OHC
expression associated with increasing Braak stage in the
ageing brain, supporting the hypothesis that cholesterol
turnover is highest during early neurodegenerative
changes [53], and suggesting that this neuroprotective
response fails with disease progression.
The pathogenesis of AD is linked to cholesterol metabo-
lism, and is associated with genetic risk factors including
apolipoprotein E (ApoE) genotype and polymorphisms in
HMGCR [54–57]. However, no association between ApoE
genotype and 24(S)-OHC was detected in this study,
although it should be noted that the sample size for the
CSF study was small. In the brain, cholesterol is almost
exclusively derived from endogenous biosynthesis, and is
regulated by the transcription factor SREBP2, which con-
trols expression of the enzymes involved in cholesterol
synthesis, including the rate-limiting enzyme HMGCR
[58]. Although neurones are capable of synthesizing their
own cholesterol, in the adult brain they rely on delivery of
cholesterol from neighbouring astrocytes via ApoE-
containing lipoproteins [59,60], but can activate the
neuronal cholesterol biosynthesis pathway in response to
oxidative stress in vitro [61]. In support of this observa-
tion, we demonstrate the significant up-regulation of cho-
lesterol biosynthesis genes in neurones with high levels of
a DDR.
In summary, we have defined themolecular signature of
a neuronal DDR, which associates with cognitive impair-
ment in older individuals with only early stage Alzheimer-
type pathology. As these individuals did not have
established Alzheimer’s neuropathology, changes in the
neuronal transcriptome are not attributable to established
AD, and may be independent of Alzheimer’s or interact
with the earliest molecular stages of the disease, or may
reflect brain ageing. No other significant brain pathologies
were present. We demonstrate an association between
a persistent neuronal DDR, increased cholesterol
biosynthesis, impaired insulin/IGF and Wnt signalling,
and increased GSK3β, which may contribute to neuronal
dysfunction and cognitive impairment. As these mecha-
nisms, operating at the earliest stages of Alzheimer’s neu-
ropathology, are potential therapeutic targets it is
important to understand their role in cognitive decline
and to develop biomarkers to identify individuals whomay
benefit from targeting such pathways at preclinical disease
stages.
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